Free Trial

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 63.40 +2.00 (+3.26%)
As of 02/21/2025 12:30 PM Eastern

NIOX vs. SN, MXCT, EKF, CREO, IUG, NCYT, IHC, POLX, AVO, and MHC

Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.

NIOX Group vs.

Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.

Smith & Nephew presently has a consensus target price of GBX 4,607.50, indicating a potential upside of 345.82%. Given Smith & Nephew's stronger consensus rating and higher probable upside, equities research analysts clearly believe Smith & Nephew is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NIOX Group has a net margin of 28.21% compared to Smith & Nephew's net margin of 5.41%. NIOX Group's return on equity of 13.29% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew5.41% 5.85% 4.51%
NIOX Group 28.21%13.29%3.95%

In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. Smith & Nephew's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£7.08B1.60£382.79M£27.7737.21
NIOX Group£3.53B7.37£995.88M£0.022,616.41

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. NIOX Group pays an annual dividend of GBX 1 per share and has a dividend yield of 1.6%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 4,126.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 35.2% of NIOX Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 46.7% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Smith & Nephew has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Smith & Nephew received 559 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 62.02% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
560
62.02%
Underperform Votes
343
37.98%
NIOX GroupOutperform Votes
1
100.00%
Underperform Votes
No Votes

Summary

Smith & Nephew beats NIOX Group on 10 of the 18 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIOX vs. The Competition

MetricNIOX GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£26.04B£3.34B£5.84B£2.64B
Dividend Yield1.66%2.42%4.75%4.98%
P/E Ratio2,616.4168.8926.15162.45
Price / Sales7.37147.36435.33313,812.88
Price / Cash11.2115.3838.0128.15
Price / Book3.524.287.645.16
Net Income£995.88M£116.55M£3.19B£5.75B
7 Day Performance5.67%0.20%-2.11%-0.99%
1 Month Performance0.32%-1.58%-0.49%-0.81%
1 Year Performance7.46%19.30%16.44%39.56%

NIOX Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
N/AGBX 63.40
+3.3%
N/A+6.4%£26.04B£3.53B2,616.4192News Coverage
High Trading Volume
SN
Smith & Nephew
3.7385 of 5 stars
GBX 1,031.50
+0.6%
GBX 4,607.50
+346.7%
-9.6%£11.31B£7.08B37.1418,452
MXCT
MaxCyte
N/AGBX 324
-1.2%
N/A-12.5%£427.69M£57.52M-11.8780
EKF
EKF Diagnostics
N/AGBX 24
-0.4%
N/A-21.2%£106.67M£49.91M22.34356News Coverage
Negative News
Gap Down
High Trading Volume
CREO
Creo Medical Group
N/AGBX 16.97
-0.2%
N/A-53.2%£68.59M£33.87M-2.68279High Trading Volume
IUG
Intelligent Ultrasound Group
N/AGBX 12.88
+1.0%
N/AN/A£42.78M£6.57M-18.9165
NCYT
Novacyt
N/AGBX 49.63
-0.9%
N/A+0.6%£34.29M£18.12M-0.91120News Coverage
Gap Down
IHC
Inspiration Healthcare Group
N/AGBX 24.80
+83.7%
N/A-44.0%£21.48M£42.87M-1.70224High Trading Volume
POLX
Polarean Imaging
N/AGBX 1.40
-5.1%
N/A-78.9%£20.55M£5.21M-0.3628
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
MHC
MyHealthChecked
N/AGBX 17.61
-2.2%
N/A+25.0%£9.16M£9.43M-8.7816Gap Up

Related Companies and Tools


This page (LON:NIOX) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners